Merit Medical Systems (NASDAQ:MMSI) and Regenicin (OTCMKTS:RGIN) are both medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their analyst recommendations, risk, dividends, profitability, valuation, earnings and institutional ownership.
Risk and Volatility
Merit Medical Systems has a beta of 1.11, indicating that its stock price is 11% more volatile than the S&P 500. Comparatively, Regenicin has a beta of 3.93, indicating that its stock price is 293% more volatile than the S&P 500.
This table compares Merit Medical Systems and Regenicin’s net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
|Merit Medical Systems||4.76%||11.26%||6.69%|
Institutional & Insider Ownership
97.8% of Merit Medical Systems shares are held by institutional investors. 5.2% of Merit Medical Systems shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.
This is a breakdown of current recommendations for Merit Medical Systems and Regenicin, as reported by MarketBeat.com.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
|Merit Medical Systems||1||0||8||0||2.78|
Merit Medical Systems currently has a consensus target price of $68.44, indicating a potential upside of 18.70%. Given Merit Medical Systems’ higher probable upside, analysts clearly believe Merit Medical Systems is more favorable than Regenicin.
Earnings and Valuation
This table compares Merit Medical Systems and Regenicin’s revenue, earnings per share and valuation.
|Gross Revenue||Price/Sales Ratio||Net Income||Earnings Per Share||Price/Earnings Ratio|
|Merit Medical Systems||$882.75 million||3.59||$42.02 million||$1.69||34.12|
Merit Medical Systems has higher revenue and earnings than Regenicin.
Merit Medical Systems beats Regenicin on 9 of the 10 factors compared between the two stocks.
About Merit Medical Systems
Merit Medical Systems, Inc. manufactures and markets disposable medical devices for interventional, diagnostic, and therapeutic procedures in cardiology, radiology, oncology, critical care, and endoscopy. The company operates through Cardiovascular and Endoscopy segments. It provides peripheral intervention products, including access, angiography, intervention, and drainage and biopsy for diagnosis and treatment of diseases in peripheral vessels and organs; and cardiac intervention products, such as access, angiography, hemostasis, intervention, and electrophysiology and cardiac rhythm management products to treat various heart conditions. The company also offers cardiovascular and critical care products to treat patients with life-threatening diseases, protect healthcare providers from exposure to bloodborne pathogens, and provide medical devices. In addition, it provides interventional oncology and spine products comprising delivery system, embolotherapy, spine ablation, and vertebral compression fracture products to treat metastatic spinal tumors, liver cancer, uterine fibroids, benign prostatic hyperplasia, vertebral compression fractures, and arteriovenous malformations and hemostatic embolization, as well as breast cancer localization and guidance products for the treatment of breast cancer. Further, the company offers non-vascular stents to treat pulmonary and gastrointestinal diseases; dilation balloons to endoscopically dilate strictures; and kits and accessories for endoscopy and bronchoscopy procedures. Additionally, it provides coated tubes and wires; and microelectromechanical system sensor components. The company sells its products to hospitals and clinic-based physicians, technicians, and nurses through its direct sales force, distributors, original equipment manufacturer partners, or custom procedure tray manufacturers in the United States and internationally. Merit Medical Systems, Inc. was founded in 1987 and is headquartered in South Jordan, Utah.
Regenicin, Inc. focuses on developing and commercializing a technology of tissue-engineered skin substitutes. The company's products are used to restore the qualities of healthy human skin for use in the treatment of burns, chronic wounds, and various plastic surgery procedures. Its development products include NovaDerm, a cultured skin substitute product for the treatment of burns; and TempaDerm to treat smaller wound areas on patients, such as ulcers. The company was formerly known as Windstar, Inc. and changed its name to Regenicin, Inc. in July 2010. Regenicin, Inc. was founded in 2007 and is based in Little Falls, New Jersey.
Receive News & Ratings for Merit Medical Systems Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Merit Medical Systems and related companies with MarketBeat.com's FREE daily email newsletter.